Experimental combo for MDS/AML shows early safety data
NCT ID NCT05275439
First seen Mar 20, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This early-phase trial tested a new drug called SL-172154, given with standard chemotherapy drugs (azacitidine with or without venetoclax), in adults with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The study aimed to find a safe dose and check for side effects. It was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott & White Research Institute
Dallas, Texas, 75246, United States
-
City of Hope
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
King's College Hospital NHS Foundation Trust
London, Denmark Hill, SE5 9RS, United Kingdom
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
UCLA Medical Center-Bowyer Oncology Center
Los Angeles, California, 90095, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University Hospitals Plymouth NHS Trust, Derriford Hospital
Crownhill, Plymouth, PL6 8DH, United Kingdom
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina, Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
VCU Massey Cancer Center
Richmond, Virginia, 23219, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.